Active ingredient description

Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX44
S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA05

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)


Aflibercept is the active ingredient of these drugs:


Australia Austria Canada Cyprus Estonia

Brazil Ecuador

Austria Brazil Cyprus Estonia Finland

Chemical formula: C₄₃₁₈H₆₇₈₈N₁₁₆₄O₁₃₀₄S₃₂
Molecular mass: 115,000 g/mol

External identifiers

CAS Substance: 862111-32-8
DrugBank Drug: DB08885
KEGG Drug: D09574
RxNorm Ingredient: 1232150
SNOMED-CT Concept: 703840003
Aflibercept (substance)
UNII Identifier: 15C2VL427D